Sacituzumab Govitecan plus Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study

被引：0

作者：

Patel, Jyoti ^{[1
]}

Cho, Byoung Chul ^{[2
]}

Dols, Manuel Cobo ^{[3
]}

Cabanillas, Roxanna Reyes ^{[4
]}

Baz, David Vicente ^{[5
]}

Pradera, Jose Fuentes ^{[6
]}

Grisanti, Salvatore ^{[7
]}

Gabayan, Afshin E. ^{[8
]}

Lee, Ki Hyeong ^{[9
]}

Cho, Eun Kyung ^{[10
]}

Mekan, Sabeen Fatima ^{[11
]}

Safavi, Farnoush ^{[11
]}

Fernando, Nalumka ^{[11
]}

Chisamore, Michael J. ^{[12
]}

Recki, Martin ^{[13
]}

机构：

[1] Robert H Lurie Comprehens Canc Ctr, Northwestern Med, Chicago, IL USA

[2] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[3] Reg & Virgen Victoria Univ Hosp, IBIMA, Malaga, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Hosp Univ Virgen Macarena, Seville, Spain

[6] Hosp Univ Virgen Valme, Seville, Spain

[7] ASST Spedali Civili Brescia, Brescia, Italy

[8] Beverly Hills Canc Ctr, Beverly Hills, CA USA

[9] Chungbuk Natl Univ Hosp, Cheongju, Chungbuk, South Korea

[10] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[11] Gilead Sci Inc, Foster City, CA USA

[12] Merck & Co Inc, Rahway, NJ USA

[13] German Ctr Lung Res DZL, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PPD01.06

引用

页码：E6 / E7

页数：2

共 50 条

[1] Sacituzumab Govitecan plus Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
Cho, B. C.
Dols, M. C.
Cabanillas, R. Reyes
Baz, D. Vicente
Pradera, J. Fuentes
Grisanti, S.
Gabayan, A. E.
Lee, K. H.
Cho, E. K.
Mekan, S.
Safavi, F.
Fernando, N.
Chisamore, M. J.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S54 - S54
[2] Sacituzumab Govitecan plus Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study
Reinmuth, Niels
Cho, Byoung Chul
Dols, Manuel Cobo
Cabanillas, Roxana Reyes
Baz, David Vicente
Pradera, Jose Fuentes
Grisanti, Salvatore
Gabayan, Afshin Eli
Lee, Ki Hyeong
Cho, Eun Kyung
Mekan, Sabeen
Safavi, Farnoush
Fernando, Nelumka
Chisamore, Michael J.
Reck, Martin
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 244 - 244
[3] Sacituzumab Govitecan plus Pembrolizumab plus Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study
Gray, J.
Neal, J.
Patel, J. D.
Liu, S. V.
Girard, N.
Reck, M.
Cappuzzo, F.
Cobo Dols, M.
Reguart, N.
Fuentes Pradera, J.
Cho, B. C.
Li, M.
Mekan, S.
Safavi, F.
Fernando, N.
Karumanchi, D.
Chisamore, M.
Garon, E. B.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S27 - S27
[4] Sacituzumab govitecan (SG) plus pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02
Patel, Jyoti D.
Cho, Byoung Chul
Cobo, Manuel
Cabanillas, Roxana Reyes
Vicente, David
Pradera, Jose Fuentes
Garon, Edward B.
Mok, Tony S. K.
Cappuzzo, Federico
Neal, Joel W.
Mekan, Sabeen Fatima
Safavi, Farnoush
Fernando, Nelumka
Chisamore, Michael Jon
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC).
Garon, Edward B.
Liu, Stephen V.
Owen, Scott Peter
Reck, Martin
Neal, Joel W.
Vicente, David
Mekan, Sabeen Fatima
Safavi, Farnoush
Fernando, Nelumka
Mok, Tony S. K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Paz-Ares, Luis G.
Juan-Vidal, Oscar
Mountzios, Giannis S.
Felip, Enriqueta
Reinmuth, Niels
de Marinis, Filippo
Girard, Nicolas
Patel, Vipul M.
Takahama, Takayuki
Owen, Scott P.
Reznick, Douglas M.
Badin, Firas B.
Cicin, Irfan
Mekan, Sabeen
Patel, Riddhi
Zhang, Eric
Karumanchi, Divyadeep
Garassino, Marina Chiara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24)
[7] Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
Gray, Jhanelle E.
Saltos, Andreas
Tanvetyanon, Tawee
Haura, Eric B.
Creelan, Ben
Antonia, Scott J.
Shafique, Michael
Zheng, Hong
Dai, Wenjie
Saller, James J.
Chen, Zhihua
Tchekmedyian, Nishan
Goas, Kristen
Thapa, Ram
Boyle, Theresa A.
Chen, Dung-Tsa
Beg, Amer A.
CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6623 - 6632
[8] Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study
Moskovitz, Mor
Okamoto, Isamu
Chen, Peng
Patel, Jilpa
Mekan, Sabeen
Pietanza, M. Catherine
Zhu, Yalin
Eiras, Renata
Tiseo, Marcello
CANCER RESEARCH, 2023, 83 (08)
[9] Phase 1 Study of Pembrolizumab and Stereotactic or Hypofractionated Radiation for Metastatic Non-small Cell Lung Cancer
Tang, C.
de Groot, P.
Hess, K.
Shabaan, S.
Gomez, D. R.
Chang, J. Y.
Lin, S. H.
Paraskevopoulos, T.
Raju, U.
Simon, G. R.
Papadimitrakopoulou, V.
Liao, Z.
Fossella, F. V.
Glisson, B. S.
Komaki, R. U.
Hahn, S. M.
Heymach, J.
Welsh, J. W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S160 - S161
[10] Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).
Xu, Nong
Ying, Kejing
Wang, Ziping
Liu, Yunpeng
Jiang, Haiping
Zhou, Hui
Wang, Shuyan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →